Answers are grounded in this paper and cite their sources.
Analysis reveals multimodal imaging biomarkers improve risk stratification for progression-free survival in multiple myeloma, suggesting enhanced predictive capability.
Purpose: To test whether internal memory states from a medical foundational segmentation model can serve as compact, mask-aware embeddings for predicting progression-free survival (PFS) in multiple myeloma (MM) from whole body [18F]FDG PET/CT. Methods: We analyzed 227 newly diagnosed MM patients with PET/CT and clinical data. For two regions of interest (spine dilated and full skeleton), we prompted MedSAM2 slice-wise using mask derived bounding boxes and cached the final spatio temporal memory tensor per modality. We compared two downsampling strategies to obtain per study embeddings: channel/memory averaging with a small CNN head, and a squeeze and excitation style depth-attention pooling. PET and CT embeddings were combined by late fusion (concatenation or scalar-gated mixing) and passed to a DeepSurv head. We evaluated image-only and multimodal (image+clinical) models with stratified 5-fold cross-validation. The primary endpoint was Harrell s c-index (mean +- SE across folds). Results: Image-only models using the averaging downsampler achieved up to 0.659 +- 0.015 c-index (PET, spine-dilated), comparable to baseline radiomics results. Multimodal models improved discrimination to 0.710 +- 0.032 (CT, spine dilated), with similar performance for other PET/CT+clinical variants (0.703 to 0.710), improving clinical-only baselines by 6.5%. Averaging consistently outperformed depth-attention; concatenation and gated fusion performed comparably. PET outperformed CT within the same mask in image-only settings. Conclusion: Mask aware embeddings extracted from a foundational segmentation model provide effective, data-efficient imaging biomarkers for MM PFS and, when fused with routine clinical covariates, significantly improve risk stratification over clinical only or radiomics baselines. This offers a practical path to prognostic modeling on small medical cohorts without feature design.
No takes yet. Share an insight, caveat, or question.
Pérez et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: